Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Saniona A/S

Home Clinical Trial Sponsors and OrganizationsSaniona A/S

Saniona A/S

Smedeland 26B, Glostrup, Hovedstaden, Denmark

Also known as:

aniona a/s

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

6

5 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

6

100.0%

Trial Status Distribution

Active, not recruiting

5

83.3%

Recruiting

1

16.7%

Clinical Trials

Trials sponsored by this organization (6)

A 36-week phase 2b, double-blind, placebo-controlled, Multi center, safety and efficacy study to evaluate overall safety and tolerability of Tesomet ( tesofensine and metoprolol) in subjects with Hypothalamic Obesity, and with an optional 38-week open-label extensio

Active, not recruiting

Nov 2021104 participants

A 16-week phase 2b, double-blind, placebo-controlled, Multi center, dose finding safety and efficacy study to evaluate overall safety and tolerability of Tesomet ( tesofensine and metoprolol) in subjects with Prader-Willi Syndrome, and with an optional 38-week open-label extensio

Active, not recruiting

Nov 2021120 participants

A 24-week phase 2, double-blind, placebo-controlled, single-centre safety and efficacy study to evaluate overall safety and tolerability of co-administration of tesofensine and metoprolol in subjects with obesity caused by an injury in hypothalamus (HIO), and with a 24-week open-label extension, in total 48 weeks

Active, not recruiting

Nov 201825 participants

Safety and efficacy of tesofensine/metoprolol in subjects with Prader-Willi syndrome

Active, not recruiting

Oct 201635 participants

Safety and efficacy of tesofensine/metoprolol in subjects with Prader-Willi syndrome

Active, not recruiting

Oct 201635 participants

Study on the investigational drug SAN711, placebo-controlled, administered to healthy adults and elderly subjects at multiple ascending oral doses to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics of SAN711 and its interaction with food

50 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials6
Approvals
News

Back to Organizations